Management & Regulatory

How is Freudenberg Medical Leading Innovation in Biopharma and MedTech?
Management & Regulatory How is Freudenberg Medical Leading Innovation in Biopharma and MedTech?

Freudenberg Medical, known for its contributions to biopharmaceuticals and medical devices, continues to enhance its product offerings and global footprint. Highlighted in an August 2024 article by Feliza Mirasol, the company's business expansion strategy focuses on custom single-use

AGC Biologics Seattle Achieves FDA Approval for New Biologic Therapies
Management & Regulatory AGC Biologics Seattle Achieves FDA Approval for New Biologic Therapies

In a significant milestone for the biopharmaceutical industry, AGC Biologics' Seattle site successfully underwent a multi-product inspection by the U.S. Food and Drug Administration (FDA) in March 2024. This comprehensive evaluation was aimed at supporting Biologics License Applications (BLA)

Analysts Bullish on Arbutus Biopharma Amid Revenue Surpassing Estimates
Management & Regulatory Analysts Bullish on Arbutus Biopharma Amid Revenue Surpassing Estimates

Arbutus Biopharma Corporation (NASDAQ: ABUS), the biopharmaceutical company known for its focus on developing treatments for chronic Hepatitis B virus (HBV) infection, recently received a noteworthy boost in its stock price target. JMP Securities raised its price objective from $4.00 to $5.00,

Biopharma Advances: Strategic Partnerships and Innovative Lab Solutions
Management & Regulatory Biopharma Advances: Strategic Partnerships and Innovative Lab Solutions

The biopharmaceutical and life sciences industry is experiencing dynamic shifts, marked by strategic partnerships, innovative laboratory products, and enhanced service offerings. Companies are increasingly focusing on forming alliances, introducing state-of-the-art equipment, and improving their

Xeris Biopharma Showing Potential Despite Recent Stock Dip and Volatility
Management & Regulatory Xeris Biopharma Showing Potential Despite Recent Stock Dip and Volatility

Xeris Biopharma Holdings Inc. (NASDAQ: XERS) recently experienced a slight dip in its stock value, closing at $2.48, down -1.59% from the previous day. However, with positive analyst ratings, significant insider buying, and strong institutional support, there are several optimistic indicators for

Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts
Management & Regulatory Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts

Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts The global biopharma market is on the cusp of remarkable transformations driven by automation, enabling more efficient production processes and improved product quality. This evolving sector is undergoing significant

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later